IRIS
BERGANTINI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.497
NA - Nord America 11.249
AS - Asia 6.468
SA - Sud America 1.108
AF - Africa 420
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 8
AN - Antartide 1
Totale 31.778
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.993
IT - Italia 3.172
RU - Federazione Russa 2.977
SG - Singapore 2.158
IE - Irlanda 1.504
GB - Regno Unito 1.495
CN - Cina 1.442
BR - Brasile 915
VN - Vietnam 880
DE - Germania 769
HK - Hong Kong 694
SE - Svezia 653
FR - Francia 583
FI - Finlandia 470
IN - India 324
ZA - Sudafrica 215
KR - Corea 213
NL - Olanda 179
ES - Italia 141
CA - Canada 137
UA - Ucraina 136
BD - Bangladesh 109
JP - Giappone 103
PL - Polonia 88
IQ - Iraq 87
MX - Messico 79
TR - Turchia 72
CZ - Repubblica Ceca 71
CI - Costa d'Avorio 57
AR - Argentina 55
AT - Austria 51
PK - Pakistan 42
NG - Nigeria 40
IR - Iran 38
ID - Indonesia 36
CH - Svizzera 33
SA - Arabia Saudita 31
BE - Belgio 30
KE - Kenya 29
UZ - Uzbekistan 29
VE - Venezuela 29
EC - Ecuador 28
MA - Marocco 28
PH - Filippine 27
AE - Emirati Arabi Uniti 25
AU - Australia 22
CL - Cile 20
CO - Colombia 19
LT - Lituania 18
PE - Perù 18
AZ - Azerbaigian 15
EG - Egitto 15
MY - Malesia 15
PT - Portogallo 15
JO - Giordania 14
BG - Bulgaria 13
IL - Israele 13
KZ - Kazakistan 13
RO - Romania 12
HU - Ungheria 11
PY - Paraguay 11
DZ - Algeria 10
EE - Estonia 10
LB - Libano 10
LV - Lettonia 10
PA - Panama 10
TN - Tunisia 10
JM - Giamaica 9
DK - Danimarca 8
GE - Georgia 8
GR - Grecia 8
NP - Nepal 8
OM - Oman 8
KG - Kirghizistan 7
BO - Bolivia 6
BY - Bielorussia 6
CY - Cipro 6
EU - Europa 6
LK - Sri Lanka 6
AL - Albania 5
HR - Croazia 5
MK - Macedonia 5
NO - Norvegia 5
QA - Qatar 5
SN - Senegal 5
TW - Taiwan 5
UY - Uruguay 5
CR - Costa Rica 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
LA - Repubblica Popolare Democratica del Laos 4
PS - Palestinian Territory 4
AM - Armenia 3
GT - Guatemala 3
RS - Serbia 3
SV - El Salvador 3
TH - Thailandia 3
AO - Angola 2
BH - Bahrain 2
KW - Kuwait 2
Totale 31.738
Salva come PNG Salva come JPEG
Città #
Dallas 2.223
Dublin 1.477
Singapore 1.359
Southend 1.187
Ashburn 912
Moscow 912
Santa Clara 769
San Jose 671
Hong Kong 641
Chandler 624
Fairfield 617
Siena 474
Beijing 406
Munich 348
Milan 347
Los Angeles 345
Lastra a Signa 340
Helsinki 328
Hefei 323
Council Bluffs 309
Ho Chi Minh City 254
New York 252
Houston 241
Woodbridge 230
Wilmington 226
Seattle 216
Hanoi 209
Florence 207
Seoul 205
Johannesburg 199
Lauterbourg 197
Princeton 186
Cambridge 179
The Dalles 134
Rome 133
Ann Arbor 126
Chicago 98
São Paulo 97
Shanghai 82
Tokyo 81
Jacksonville 74
Warsaw 74
Bengaluru 73
Orem 73
Frankfurt am Main 68
Redondo Beach 68
Buffalo 65
Dong Ket 64
Turku 64
Fremont 63
London 63
Nuremberg 63
Lappeenranta 59
Málaga 59
San Mateo 59
Abidjan 57
Boardman 55
Düsseldorf 52
San Diego 52
Chennai 51
Da Nang 49
Portsmouth 48
Dearborn 47
Brooklyn 41
Montreal 41
Brno 40
Toronto 38
Haiphong 37
Stockholm 37
Amsterdam 35
Washington 34
Baghdad 33
Abuja 32
Denver 32
Poplar 32
Atlanta 31
Manchester 31
Phoenix 31
Brescia 29
Boston 28
Rio de Janeiro 26
Tashkent 26
Vienna 26
Mumbai 25
Naples 25
Paris 25
Gavirate 24
Olomouc 23
Padova 23
Salt Lake City 23
San Francisco 23
Zurich 23
Dhaka 22
Mexico City 22
Hyderabad 21
Newark 21
Agliana 19
New Delhi 19
Ankara 17
Belo Horizonte 17
Totale 20.596
Salva come PNG Salva come JPEG
Nome #
A first update on mapping the human genetic architecture of COVID-19 575
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 574
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 499
Genetic mechanisms of critical illness in COVID-19 409
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 387
An explainable model of host genetic interactions linked to COVID-19 severity 365
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 348
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 342
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 337
Pathogen-sugar interactions revealed by universal saturation transfer analysis 323
null 320
Peripheral biomarkers' panel for severe COVID-19 patients 316
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 311
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 292
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 286
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 283
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 279
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 278
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 272
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues 271
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 271
Immune modulatory effects of novel monoclonal antibodies target therapies in severe eosinophilic asthma patients 269
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 261
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 253
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 253
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 250
Serial KL-6 measurements in COVID-19 patients 245
Prognostic bioindicators in severe COVID-19 patients 244
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting 243
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 242
Serum amyloid A in patients with idiopathic pulmonary fibrosis 236
A real-life experience with ImmunoCAP ISAC: the advantages of a new diagnostic method 235
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 235
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 234
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 234
AB0611 Neutrophil extracellular traps and interstitial lung disease in ANCA-associated vasculitis: a scoping review 232
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 232
Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: A pivotal study 231
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 224
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis 221
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 219
NK and NKT-like cells in granulomatous and fibrotic lung diseases 216
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 216
Galactin-1, 3 and 9: Potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases 215
BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures 214
Immune-Checkpoint Expression on CD4, CD8 and NK Cells in Blood, Bronchoalveolar Lavage and Lymph Nodes of Sarcoidosis 213
Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder 213
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 211
A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad 211
Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II 211
Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies 204
WES profiling of COVID-19 204
Altered serum concentrations of IL-8, IL-32 and IL-10 in patients with lung impairment 6 months after COVID-19 203
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy 202
Serum amyloid A: A potential biomarker of lung disorders 201
Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes 200
Whole-genome sequencing reveals host factors underlying critical COVID-19 198
Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting 196
Systematic review and metanalysis of oncomarkers in ipf patients and serial changes of oncomarkers in a prospective italian real-life case series 195
Alteration of Immune-checkpoint after specific stimulation with CMV antigens in pre-LTx patients 194
Multi-Omics Integrative Approach of Extracellular Vesicles: A Future Challenging Milestone 194
Collagen Type IV Alpha 5 Chain in Bronchiolitis Obliterans Syndrome After Lung Transplant: The First Evidence 192
Clinical and molecular characterization of COVID-19 hospitalized patients 191
Regulatory and Effector Cell Disequilibrium in Patients with Acute Cellular Rejection and Chronic Lung Allograft Dysfunction after Lung Transplantation: Comparison of Peripheral and Alveolar Distribution 191
Protective role of a TMPRSS2 variant on severe COVID-19 outcome in young males and elderly women 189
Effects of rituximab therapy on B cell differentiation and depletion 188
Brain neuronal and glial damage during acute COVID-19 infection in absence of clinical neurological manifestations 187
The Role of Urinary Calcium and Chitotriosidase in a Cohort of Chronic Sarcoidosis Patients 187
Peripheral and alveolar biomarkers of fibrotic hypersensitivity pneumonitis 187
Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment 187
Oxygen Therapy during Exercise in Patients with Interstitial Lung Diseases 180
Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab 180
Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: a comprehensive review 176
Prognostic role of KL-6 in lymphangioleiomyomatosis patients 176
Peripheral lymphocyte subset monitoring in COVID-19 Italian patients 174
Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis 174
Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study 173
Differential redox proteomic profiles of serum from severe asthma patients after one month of Benralizumab and Mepolizumab treatment 172
The Effects of Interstitial Lung Diseases on Alveolar Extracellular Vesicles Profile: A Multicenter Study 171
Serum CD59: a novel biomarker of idiopathic pulmonary fibrosis? 171
A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists 171
CD103 Expression on Regulatory and Follicular T Cells in Lymph Nodes, Bronchoalveolar Lavage Fluid and Peripheral Blood of Sarcoidosis Patients 169
Proteomic characterization of idiopathic pulmonary fibrosis patients: stable versus acute exacerbation 169
Common molecular pathways targeted by nintedanib in cancer and IPF: a bioinformatic study 169
Immunologic responses to antifibrotic treatment in IPF patients 165
Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases 163
Characterization of NKG2-A/-C, Kir and CD57 on NK Cells Stimulated with pp65 and IE-1 Antigens in Patients Awaiting Lung Transplant 161
Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a new protocol for investigating the mechanisms of idiopathic pulmonary fibrosis 160
Exploring the interaction between fractional exhaled nitric oxide and biologic treatment in severe asthma: a systematic review 159
Cytological analysis of bronchoalveolar lavage fluid in asbestos-exposed workers: BALF features in asbestos exposed workers 158
The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis 157
Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy 157
Prevalence of myositis specific and associated antibodies in a cohort of patients affected by idiopathic NSIP and no hint of inflammatory myopathies 153
Serial investigation of Angiotensin-Converting Enzyme in sarcoidosis patients treated with Angiotensin-Converting Enzyme Inhibitor 153
Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study 153
Efficacy and safety of a step-down regimen of low dosage of glucocorticoids combined with early administration of synthetic or biologic immunosuppressants in anti-synthetase syndrome: A pilot study 150
Cytokine profiles in the detection of severe lung involvement in hospitalized patients with COVID-19: The IL-8/IL-32 axis 148
Markers of Bronchiolitis Obliterans Syndrome after Lung Transplant: Between Old Knowledge and Future Perspective 148
The Role of Galectins in Chronic Lung Allograft Dysfunction 147
Rituximab-induced hypogammaglobulinaemia in patients affected by idiopathic inflammatory myopathies: a multicentre study 146
Totale 22.844
Salva come PNG Salva come JPEG
Categoria #
all - tutte 109.542
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 109.542
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021566 0 0 0 0 0 0 0 0 0 147 217 202
2021/20222.306 175 268 201 159 113 100 95 104 101 295 262 433
2022/20232.707 175 294 334 266 155 479 283 236 183 117 111 74
2023/20243.095 119 95 316 163 158 661 869 147 43 103 119 302
2024/20256.894 603 268 757 395 788 424 381 419 535 350 627 1.347
2025/202614.372 1.057 1.926 1.751 1.859 3.101 584 2.028 485 607 974 0 0
Totale 32.601